AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12033698 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve-Step Facilitation (TSF) therapy
Number of subjects: 205
Study 12033698 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT) and Motivational Enhancement Therapy (MET)
Number of subjects: 205
Study 10204758 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy measures (Arthritis Self Efficacy Scale - ASES)
Number of subjects: 128
Study 7564453 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tranexamic acid (10 gm intravenously over 20 minutes before sternotomy and a placebo infusion over 5 hours)
Number of subjects: 150
Study 7564453 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tranexamic acid (10 gm intravenously over 20 minutes and another 10 gm infused over 5 hours)
Number of subjects: 150
Study 7564453 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline solution bolus and infusion over 5 hours)
Number of subjects: 150
Study 7564453 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tranexamic acid (10 gm)
Number of subjects: 150
Study 7564453 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued tranexamic acid infusion (10 gm over 5 hours)
Number of subjects: 150
Study 2075481 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg (regimen A)
Number of subjects: 34
Study 2075481 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 600 mg (regimen B)
Number of subjects: 34
Study 6992823 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (400-800 mg daily)
Number of subjects: 40
Study 6992823 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (1200-1600 mg daily)
Number of subjects: 40
Study 6992823 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 40
Study 6992823 — intervention group
Group type: COMPARATOR
Intervention: Acebutolol (400-800 mg daily)
Number of subjects: 40
Study 30549273 — intervention group
Group type: EXPERIMENTAL
Intervention: hrHPV testing every 5 years
Number of subjects: 1008
Study 30549273 — intervention group
Group type: COMPARATOR
Intervention: Cytology testing every 3 years
Number of subjects: 1008
Study 30549273 — intervention group
Group type: EXPERIMENTAL
Intervention: Five different combinations of abnormal screening test results
Number of subjects: 1008
Study 30549273 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term anxiety or depression scores (4-24 months after screening)
Number of subjects: 1008
Study 30527615 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 1366
Study 30527615 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 1366
Study 27662018 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (4 cycles of standard anthracycline-based chemotherapy)
Number of subjects: 434
Study 27662018 — intervention group
Group type: COMPARATOR
Intervention: No induction chemotherapy
Number of subjects: 434
Study 27662018 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (per protocol)
Number of subjects: 434
Study 27662018 — intervention group
Group type: COMPARATOR
Intervention: No induction chemotherapy (per protocol)
Number of subjects: 434
Study 27662018 — intervention group
Group type: EXPERIMENTAL
Intervention: MEL140 (high-dose melphalan)
Number of subjects: 434
Study 27662018 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization chemotherapy and tandem MEL140
Number of subjects: 434
Study 24568260 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigger point dry needling (TrPDN)
Number of subjects: 17
Study 24568260 — intervention group
Group type: COMPARATOR
Intervention: No intervention (waiting list)
Number of subjects: 17
Study 22248762 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL to 0.5% ropivacaine
Number of subjects: 60
Study 22248762 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL to 0.5% ropivacaine
Number of subjects: 60
Study 22248762 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL to 1% ropivacaine
Number of subjects: 60
Study 20389068 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual TTP-DWI mismatch assessment by experienced rater
Number of subjects: 99
Study 20389068 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual TTP-DWI mismatch assessment by inexperienced raters
Number of subjects: 99
Study 20389068 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual T(max)-DWI mismatch assessment by experienced rater
Number of subjects: 99
Study 20389068 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual T(max)-DWI mismatch assessment by inexperienced raters
Number of subjects: 99
Study 20389068 — intervention group
Group type: COMPARATOR
Intervention: Volumetric calculation of perfusion-diffusion mismatch
Number of subjects: 99
Study 17118993 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (45 min at 95% of lactate threshold)
Number of subjects: 9
Study 17118993 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 9
Study 17118993 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterregulatory hormones during exercise
Number of subjects: 9
Study 17118993 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 9
Study 17118993 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 9
Study 17118993 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 9
Study 17118993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol
Number of subjects: 9
Study 16301144 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable osteosynthesis materials
Number of subjects: 54
Study 16301144 — intervention group
Group type: COMPARATOR
Intervention: Titanium fixation system (rescue osteosynthesis)
Number of subjects: 54
Study 11916896 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive, moderate intensity, group exercise
Number of subjects: 139
Study 11916896 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily micronutrient enriched foods (25‐100% recommended daily amount)
Number of subjects: 139
Study 11916896 — intervention group
Group type: EXPERIMENTAL
Intervention: Both exercise and micronutrient supplementation
Number of subjects: 139
Study 11916896 — intervention group
Group type: COMPARATOR
Intervention: Neither intervention (attention control and placebo)
Number of subjects: 139
Study 9859596 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipidic matrix of Gelucire 44/14
Number of subjects: 8
Study 9859596 — intervention group
Group type: COMPARATOR
Intervention: Commercially available tablet (control)
Number of subjects: 8
Study 7889183 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral TRH (40 mg, 12 hourly) plus metoclopramide (10 mg, 8 hourly)
Number of subjects: 7
Study 7889183 — intervention group
Group type: COMPARATOR
Intervention: Oral TRH (40 mg, 12 hourly) plus placebo (one capsule, 8 hourly)
Number of subjects: 7
Study 2231049 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive care services provided by physicians
Number of subjects: 0
Study 2231049 — intervention group
Group type: EXPERIMENTAL
Intervention: U.S. Preventive Services Task Force's guide to clinical preventive services
Number of subjects: 0
Study 2231049 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive care including prevention
Number of subjects: 0
Study 2231049 — intervention group
Group type: EXPERIMENTAL
Intervention: External pressures affecting physician-patient relationship
Number of subjects: 0
Study 857102 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone reminder call
Number of subjects: 98
Study 857102 — intervention group
Group type: COMPARATOR
Intervention: No call (Control)
Number of subjects: 98
Study 30538278 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (specifics not provided)
Number of subjects: 219
Study 29879520 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 liters of normal saline (NS)
Number of subjects: 157
Study 29879520 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 liters lactated Ringer's (LR)
Number of subjects: 157
Study 29879520 — intervention group
Group type: COMPARATOR
Intervention: No IV fluid (noIVF)
Number of subjects: 157
Study 27574260 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml of 0.375% ropivacaine plus tramadol 50 mg
Number of subjects: 60
Study 27574260 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml of 0.375% ropivacaine plus tramadol 100 mg
Number of subjects: 60
Study 27574260 — intervention group
Group type: COMPARATOR
Intervention: No preoperative femoral nerve block (control)
Number of subjects: 60
Study 27574260 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block with ropivacaine (no tramadol)
Number of subjects: 60
Study 27574260 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block (all groups)
Number of subjects: 60
Study 25048048 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid fixation (1 u‐HA/PLLA plate and 4 mono‐cortical screws and a bi‐cortical screw in each side)
Number of subjects: 66
Study 25048048 — intervention group
Group type: COMPARATOR
Intervention: Conventional fixation (1 u‐HA/PLLA plate and 4 mono‐cortical screws in each side)
Number of subjects: 66
Study 22949150 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,250 mg/m² days 1 and 8 of a 3-week cycle)
Number of subjects: 464
Study 22949150 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day)
Number of subjects: 464
Study 22949150 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 464
Study 22949150 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line pemetrexed (500 mg/m² once every 21 days)
Number of subjects: 464
Study 20594347 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-directed intervention consisting of 4 meetings with a nurse, 1 meeting with an occupational physician and supervisor, and letters from the treating physician to enhance communication.
Number of subjects: 0
Study 20594347 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 0
Study 17604912 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg cortisol (oral administration)
Number of subjects: 20
Study 17604912 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral administration)
Number of subjects: 20
Study 16100331 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally competent dietary self‐management intervention consisting of 4 weekly classes in low‐fat dietary strategies, 5 monthly peer‐professional group discussions, and weekly telephone follow‐up
Number of subjects: 97
Study 16100331 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 97
Study 16100331 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally competent dietary self‐management intervention
Number of subjects: 97
Study 12859585 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral eletriptan 40 mg
Number of subjects: 0
Study 12859585 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral eletriptan 80 mg
Number of subjects: 0
Study 12859585 — intervention group
Group type: COMPARATOR
Intervention: Oral sumatriptan 50 mg
Number of subjects: 0
Study 12859585 — intervention group
Group type: COMPARATOR
Intervention: Oral sumatriptan 100 mg
Number of subjects: 0
Study 10370679 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g Ceftriaxone
Number of subjects: 82
Study 10370679 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g Ceftriaxone
Number of subjects: 82
Study 10370679 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (1 g or 2 g)
Number of subjects: 82
Study 8958612 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (Coumadin) therapy with guidelines for initiation, monitoring, and reversal
Number of subjects: 0
Study 1515384 — intervention group
Group type: COMPARATOR
Intervention: 1 ml physiologic saline
Number of subjects: 100
Study 1515384 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 ml (1 mg) 0.5% phenylephrine plus 0.8 ml normal saline
Number of subjects: 100
Study 1515384 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 ml phenylephrine plus 0.6 ml normal saline
Number of subjects: 100
Study 1515384 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 ml phenylephrine plus 0.4 ml normal saline
Number of subjects: 100
Study 1515384 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 ml phenylephrine plus 0.2 ml normal saline
Number of subjects: 100
Study 6093522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g daily
Number of subjects: 84
Study 6093522 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin 3 to 4 g daily
Number of subjects: 84
Study 30449536 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular dexamethasone at 10 mg
Number of subjects: 220
Study 30449536 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular methylprednisolone acetate at 160 mg
Number of subjects: 220
Study 27734464 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 25 mg once daily
Number of subjects: 155
Study 27734464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 25526812 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-dimensional family therapy (MDFT)
Number of subjects: 5
Study 25526812 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 5
Study 23826842 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid (DA) DVD
Number of subjects: 30
Study 23826842 — intervention group
Group type: COMPARATOR
Intervention: Standard information (control group)
Number of subjects: 30
Study 23826842 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 30
Study 23826842 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy (RP)
Number of subjects: 30
Study 20883990 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma preptin levels in women with PCOS
Number of subjects: 0
Study 20883990 — intervention group
Group type: COMPARATOR
Intervention: Control group (women without PCOS)
Number of subjects: 0
Study 19182155 — intervention group
Group type: EXPERIMENTAL
Intervention: Trihexyphenidyl
Number of subjects: 16
Study 19182155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17443731 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined brief psychosexual intervention (CBPI)
Number of subjects: 20
Study 15295690 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 197
Study 15295690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 12566370 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat (5 micro g/min)
Number of subjects: 24
Study 12566370 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat (5 micro g/min) with bradykinin (100 ng/min)
Number of subjects: 24
Study 12566370 — intervention group
Group type: COMPARATOR
Intervention: HOE 140 (100 microg/kg intravenously)
Number of subjects: 24
Study 10356958 — intervention group
Group type: EXPERIMENTAL
Intervention: LA-1 oncoprotein
Number of subjects: 46
Study 10356958 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 16 E2
Number of subjects: 46
Study 10356958 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant vaccinia virus HSV-2 gD protein
Number of subjects: 46
Study 10356958 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of LA-1 and HPV16 E2 seropositivity
Number of subjects: 46
Study 7972348 — intervention group
Group type: EXPERIMENTAL
Intervention: Propentofylline at 0.9 g/d
Number of subjects: 190
Study 7972348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 2570005 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg at night)
Number of subjects: 119
Study 2570005 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (800 mg at night)
Number of subjects: 119
Study 16801 — intervention group
Group type: EXPERIMENTAL
Intervention: triazolam 0-5 mg
Number of subjects: 104
Study 16801 — intervention group
Group type: COMPARATOR
Intervention: triazolam 0-25 mg
Number of subjects: 104
Study 31663683 — intervention group
Group type: EXPERIMENTAL
Intervention: Competing risk nomogram using the model of the worse characteristics
Number of subjects: 10319
Study 31663683 — intervention group
Group type: EXPERIMENTAL
Intervention: Competing risk nomogram using the model of bilateral tumors
Number of subjects: 10319
Study 31663683 — intervention group
Group type: EXPERIMENTAL
Intervention: Competing risk nomogram using the model of worse tumor
Number of subjects: 10319
Study 31663683 — intervention group
Group type: EXPERIMENTAL
Intervention: Competing risk nomogram using the model of first tumor
Number of subjects: 10319
Study 31663683 — intervention group
Group type: EXPERIMENTAL
Intervention: Competing risk nomogram using the model of second tumor
Number of subjects: 10319
Study 31663683 — intervention group
Group type: EXPERIMENTAL
Intervention: Net reclassification index for 3-year and 5-year survival
Number of subjects: 10319
Study 31663683 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration curves
Number of subjects: 10319
Study 27182765 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace mindfulness training (WMT)
Number of subjects: 113
Study 25979316 — intervention group
Group type: EXPERIMENTAL
Intervention: Take‐N‐Slide(™)
Number of subjects: 53480
Study 25979316 — intervention group
Group type: EXPERIMENTAL
Intervention: RxTimerCap(™)
Number of subjects: 53480
Study 25979316 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard pillbox
Number of subjects: 53480
Study 25979316 — intervention group
Group type: COMPARATOR
Intervention: Control group (no device)
Number of subjects: 53480
Study 23668675 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat-enriched diet
Number of subjects: 27
Study 23668675 — intervention group
Group type: COMPARATOR
Intervention: Standard dietary advice
Number of subjects: 27
Study 20636429 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized 3% hypertonic saline (HS)
Number of subjects: 126
Study 20636429 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 126
Study 19629539 — intervention group
Group type: EXPERIMENTAL
Intervention: SCION program (advisory consultation, optimizing emesis prophylaxis, nutrition counseling, relaxation)
Number of subjects: 208
Study 19629539 — intervention group
Group type: COMPARATOR
Intervention: Standard antiemetic treatment and standard care (Control group)
Number of subjects: 208
Study 17432400 — intervention group
Group type: EXPERIMENTAL
Intervention: Variolink 2/Syntac Classic (group 1)
Number of subjects: 40
Study 17432400 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifix DC/Solobond Plus (group 2)
Number of subjects: 40
Study 17432400 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibra/Prime & Bond NT combinations (group 3)
Number of subjects: 40
Study 17432400 — intervention group
Group type: COMPARATOR
Intervention: Zinc-phosphate cement (control group 4)
Number of subjects: 40
Study 15142023 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine powder in solution (CP) - 20 g.day(‐1) x 6 days
Number of subjects: 11
Study 15142023 — intervention group
Group type: COMPARATOR
Intervention: Creatine serum (CS) - 5 ml.day(‐1) x 6 days
Number of subjects: 11
Study 11701194 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 standard units of alcohol (40 g) under fasting conditions
Number of subjects: 7
Study 11701194 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 standard units of alcohol (40 g) after food consumption
Number of subjects: 7
Study 11701194 — intervention group
Group type: COMPARATOR
Intervention: Placebo under fasting conditions
Number of subjects: 7
Study 11701194 — intervention group
Group type: COMPARATOR
Intervention: Placebo after food consumption
Number of subjects: 7
Study 9683155 — intervention group
Group type: EXPERIMENTAL
Intervention: Nidek ARK-900 objective refractor
Number of subjects: 100
Study 9683155 — intervention group
Group type: COMPARATOR
Intervention: Retinoscopy
Number of subjects: 100
Study 7995664 — intervention group
Group type: EXPERIMENTAL
Intervention: Constrictive pericarditis
Number of subjects: 33
Study 7995664 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative normal hemodynamics (n = 12)
Number of subjects: 33
Study 7995664 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative persisting hemodynamic abnormality (n = 6)
Number of subjects: 33
Study 7995664 — intervention group
Group type: COMPARATOR
Intervention: Restrictive cardiomyopathy
Number of subjects: 33
Study 7995664 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 33
Study 1673942 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (Aldactone)
Number of subjects: 43
Study 1673942 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (Gestapuran)
Number of subjects: 43
Study 1673942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 365544 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol and bendrofluazide (once daily dosage)
Number of subjects: 44
Study 365544 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol and bendrofluazide (twice daily dosage)
Number of subjects: 44
Study 30873703 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence angiography (FA) during IPAA surgery
Number of subjects: 32
Study 30873703 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (no FA)
Number of subjects: 32
Study 28093841 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg daily)
Number of subjects: 9306
Study 28093841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9306
Study 26229148 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT/CT
Number of subjects: 1508
Study 26229148 — intervention group
Group type: COMPARATOR
Intervention: Planar Imaging (PI)
Number of subjects: 1508
Study 23500262 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg
Number of subjects: 7817
Study 23500262 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg
Number of subjects: 7817
Study 23500262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7817
Study 23500262 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (both doses)
Number of subjects: 7817
Study 21447465 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual scanning
Number of subjects: 10
Study 21447465 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental practice
Number of subjects: 10
Study 21447465 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10